Adrenomed produces Adrecizumab to decrease death rates from sepsis The German corporation Adrenomed AG today announced its intentions to contribute to the reduced amount of mortality from sepsis and septic shock. Sepsis is an advanced systemic contamination that travels via the blood stream to numerous of the body's vital organs, that may lead to death and disability. Adrenomed AG is rolling out the new first-in-class compound, Adrecizumab. The medication targets the vasoactive hormone adrenomedullin as one of the crucial mediators during sepsis and septic shock. Adrecizumab is normally a humanized monoclonal anti-adrenomedullin antibody, which modulates the adrenomedullin bioactivity and shows to stabilize circulation and renal function in animal models of septic shock.Historically, these target infections have triggered lethal outbreaks in poultry. If indeed they acquire the ability to be transmitted from human to human efficiently, they could potentially cause a worldwide pandemic. Given the prospect of H5, H7 and H9 avian influenza to jump species and result in a public health crisis, we concentrated our initiatives on developing reagents to identify avian influenza strains which have the potential to trigger pandemic disease in humans, explained Cohava Gelber, PhD/MBA, ATCC Chief Technology and Science Officer. The antibody-based diagnostic test that’s being developed by ATCC is designed to provide information about the virus subtype, a capability that’s not found in existing fast influenza diagnostics currently.